Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 11:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 101 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lipoic acid Clear all
Recruiting Phase 2 Interventional Accepts healthy volunteers

Pilot Study: Impact of Biomarker-Guided Dietary Supplementation on Quality-of-Life Measures in Subjects With Chronic Pain

NCT06247813
View directory record Official record
Conditions
Chronic Pain
Interventions
Inflammation Support Formula, Nerve Health Formula, Redox Support Formula
Dietary Supplement
Lead sponsor
Ethos Research & Development
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Newport, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 27, 2026, 11:23 PM EDT
Completed Phase 2 Interventional

Immune Restoration by Lipoic Acid in AIDS

NCT00033176
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
Alpha Lipoic Acid
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
San Francisco, California • San Jose, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2006 · Synced Sep 27, 2026, 11:23 PM EDT
Recruiting Not applicable Interventional

Optimizing Integrative Oncology Approaches to Address Chemotherapy-induced Peripheral Neuropathy in Gastrointestinal (GI) Cancer Patients: A SMART Pilot Study

NCT07501663
View directory record Official record
Conditions
Peripheral Neuropathy
Interventions
Tai Chi/Qi Gong, α- Lipoic acid, Acupuncture
Behavioral · Dietary Supplement · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 27, 2026, 11:23 PM EDT
Not listed Not applicable Interventional

Impact of Two Dietary Interventions on Simple Carbohydrate Intolerance

NCT06057376
View directory record Official record
Conditions
Carbohydrate Intolerance
Interventions
Low-FODMAP diet group (LFD), Low Sugar diet group (LAS)
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
5 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Springfield, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 27, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Results available

Lipoic Acid for Progressive Multiple Sclerosis (MS)

NCT03161028
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Lipoic acid, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Sep 27, 2026, 11:23 PM EDT
Completed Early Phase 1 Interventional

Exercise and NO in HFrEF

NCT03136029
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
Antioxidant, Tetrahydrobiopterin (BH4), Exercise training
Dietary Supplement · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 27, 2026, 11:23 PM EDT
Not listed Phase 1 Interventional

Does Clinical Treatment of Mitochondrial Dysfunction Impact Autism Spectrum Disorder (ASD)?

NCT02348125
View directory record Official record
Conditions
Autism Spectrum Disorders, Mitochondrial Diseases
Interventions
Mitochondrial Cocktail
Drug
Lead sponsor
Drexel University
Other
Eligibility
3 Years to 12 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Sep 27, 2026, 11:23 PM EDT
Completed Phase 2 Interventional

Tocopherols and Alpha Lipoic Acid Treatment Chronic Kidney Disease (TALAT)

NCT00308971
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Alpha, gamma, beta, and delta (mixed) tocopherols, alpha lipoic acid, placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Portland, Maine • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 8, 2009 · Synced Sep 27, 2026, 11:23 PM EDT
Completed Phase 1 Interventional

A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis

NCT00676156
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
oral lipoic acid (LA), lipoic acid (LA) with fish oil and LA without fish oil, R lipoic acid
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 5, 2012 · Synced Sep 27, 2026, 11:23 PM EDT
Active, not recruiting Phase 2 Interventional

MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis

NCT02171104
View directory record Official record
Conditions
Mucopolysaccharidosis Disorders, Hurler Syndrome, Hunter Syndrome, Maroteaux Lamy Syndrome, Sly Syndrome, Alpha-Mannosidosis, Fucosidosis, Aspartylglucosaminuria, Glycoprotein Metabolic Disorders, Sphingolipidoses, Recessive Leukodystrophies, Globoid Cell Leukodystrophy, Metachromatic Leukodystrophy, Niemann-Pick B, Niemann-Pick C Subtype 2, Sphingomyelin Deficiency, Peroxisomal Disorders, Adrenoleukodystrophy With Cerebral Involvement, Zellweger Syndrome, Neonatal Adrenoleukodystrophy, Infantile Refsum Disease, Acyl-CoA Oxidase Deficiency, D-Bifunctional Enzyme Deficiency, Multifunctional Enzyme Deficiency, Alpha-methylacyl-CoA Racmase Deficiency, Mitochondrial Neurogastrointestingal Encephalopathy, Severe Osteopetrosis, Hereditary Leukoencephalopathy With Axonal Spheroids (HDLS; CSF1R Mutation), Inherited Metabolic Disorders
Interventions
Stem Cell Transplantation, IMD Preparative Regimen, Osteopetrosis Only Preparative Regimen, Osteopetrosis Haploidentical Only Preparative Regimen, cALD SR-A (Standard-Risk, Regimen A), cALD SR-B (Standard-Risk, Regimen B), cALD HR-D (High-Risk, Regimen C), cALD HR-D (High-Risk, Regimen D)
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 27, 2026, 11:23 PM EDT
Completed Not applicable Interventional

Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension

NCT00795262
View directory record Official record
Conditions
Diabetes, Hypertension
Interventions
Quinapril (Accupril) plus Alpha Lipoic Acid, accupril, placebo, accupril, alpha lipoic acid
Drug
Lead sponsor
InVasc Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Tucker, Georgia
Source: ClinicalTrials.gov public record
Updated May 4, 2011 · Synced Sep 27, 2026, 11:23 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Alpha Lipoic Acid in Geographic Atrophy

NCT02613572
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
alpha lipoic acid, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years to 90 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
5
States / cities
Iowa City, Iowa • Teaneck, New Jersey • Eugene, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 27, 2026, 11:23 PM EDT
Completed Phase 2 Interventional

INV-144 Versus Losartan in Hypertension and Type 2 Diabetes Mellitus Patients With Macroalbuminuria

NCT01398423
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
Active Control, INV-144
Drug
Lead sponsor
InVasc Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
19
States / cities
Garden Grove, California • La Mesa, California • Northridge, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Sep 27, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Results available

Provision of Antioxidant Therapy in Hemodialysis (PATH) Study

NCT00237718
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
Alpha, gamma, beta, and delta (mixed) tocopherols, Alpha lipoic acid, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 10, 2012 · Synced Sep 27, 2026, 11:23 PM EDT
Completed Not applicable Interventional

An Open-Label Pilot Trial of Alpha Lipoic Acid (ALA) for Weight Loss in Schizophrenia

NCT01355952
View directory record Official record
Conditions
Obesity, Weight Loss, Schizophrenia
Interventions
Alpha Lipoic Acid
Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Sep 27, 2026, 11:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Alpha Lipoic Acid and Insulin Resistance

NCT00845156
View directory record Official record
Conditions
Insulin Resistance
Interventions
Alpha Lipoic Acid
Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
20 Years to 60 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Sep 27, 2026, 11:23 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1

NCT04916327
View directory record Official record
Conditions
Peripheral Vascular Diseases
Interventions
Antioxidant, Placebo
Dietary Supplement
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 35 Years
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 27, 2026, 11:23 PM EDT
Withdrawn Phase 1Phase 2 Interventional

CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer

NCT03370159
View directory record Official record
Conditions
Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
6,8-Bis(benzylthio)octanoic Acid, Docetaxel, Pharmacological Study
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 27, 2026, 11:23 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin

NCT00477607
View directory record Official record
Conditions
Ototoxicity, Unspecified Adult Solid Tumor
Interventions
alpha-lipoic acid, Audiology, laboratory biomarker analysis, Placebo
Drug · Behavioral · Biological
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Sep 27, 2026, 11:23 PM EDT
Completed Phase 1 Interventional

Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis

NCT03493841
View directory record Official record
Conditions
Multiple Sclerosis, Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Interventions
Alpha Lipoic Acid
Drug
Lead sponsor
Rebecca Spain
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Sep 27, 2026, 11:23 PM EDT
Completed Phase 1 Interventional

CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

NCT01839981
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
6,8-bis(benzylthio)octanoic acid
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Sep 27, 2026, 11:23 PM EDT
Completed Phase 1Phase 2 Interventional

Painful HIV Neuropathy and Alpha-Lipoic Acid

NCT00079807
View directory record Official record
Conditions
HIV, Peripheral Neuropathy
Interventions
Alpha-Lipoic Acid
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2008 · Synced Sep 27, 2026, 11:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance

NCT00122447
View directory record Official record
Conditions
Impaired Glucose Tolerance, Prediabetic State
Interventions
Aspirin, Alpha lipoic acid, Olmesartan, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Sep 27, 2026, 11:23 PM EDT
Completed Phase 1 Interventional

CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

NCT01931787
View directory record Official record
Conditions
Recurrent Small Cell Lung Cancer
Interventions
6,8-bis(benzylthio)octanoic acid
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Sep 27, 2026, 11:23 PM EDT